EQ Eloquence Deep with Lidocaine (1.1ml)
Eloquence
Dermal FillerHigh-density cross-linked hyaluronic acid dermal filler
Certifications
- CE Marked hyaluronic acid dermal filler for aesthetic indications in accordance with European medical device regulations.
- Manufactured by Jetema Co., Ltd. under certified quality management systems (including ISO 13485 for medical devices).
- Uses high Purity, non Animal hyaluronic acid with low endotoxin content and controlled residual cross Linker levels in line with international safety standards for HA fillers.
- CE Marked hyaluronic acid dermal filler for aesthetic indications in accordance with European medical device regulations.
- Manufactured by Jetema Co., Ltd. under certified quality management systems (including ISO 13485 for medical devices).
- Uses high Purity, non Animal hyaluronic acid with low endotoxin content and controlled residual cross Linker levels in line with international safety standards for HA fillers.
High-density cross-linked hyaluronic acid dermal filler
Description
EQ Eloquence Deep with Lidocaine (1.1ml) is a viscous, fully cross-linked, high-density hyaluronic acid dermal filler containing lidocaine for enhanced patient comfort. As part of the Eloquence range, it is a high-elasticity HA filler specifically designed for facial augmentation in areas where more structure and lift are required. The thicker, long-lasting gel is used by trained professionals to fill and sculpt cheeks, chin and lips, lifting and plumping the skin while smoothing the appearance of deep wrinkles and folds. Formulated with 24 mg/ml non-animal hyaluronic acid and 0.3% lidocaine, it offers strong viscoelasticity and an elastic HIVE gel structure (500 conditional viscosity index), giving the injector a product that is easy to shape and that maintains natural facial movement. Typical clinical longevity is around 6–12 months depending on indication, injection technique and patient lifestyle.
Bnefits
- High-density, fully cross-linked hyaluronic acid gel designed for deep volume restoration and structural facial contouring.
- Thicker, highly elastic filler ideal for cheeks, chin and lips where more lift and projection are required.
- Contains 0.3% lidocaine to reduce injection discomfort and improve patient experience.
- 500 conditional viscosity index and elastic HIVE structure provide strong viscoelasticity, allowing sculpting while maintaining natural facial movement.
- Longer-lasting formula, with results typically maintained for 6–12 months depending on treatment area and patient factors.
- Non-animal, highly purified hyaluronic acid with low endotoxin levels, supporting safety and tolerability.
- CE-marked dermal filler manufactured by an established Korean HA producer (Jetema), known for quality and consistency.
Indications
- Facial augmentation nearer the bone, including deep structural support in the mid- and lower face.
- Jawline sculpting and contour definition.
- Cheekbone sculpting and mid-face volumisation.
- Chin augmentation and profile balancing.
- Plumping and lifting of the skin in areas of pronounced volume loss.
- Reduction of medium-to-deep wrinkles and folds such as nasolabial folds and marionette lines (when clinically appropriate).
Composition
- Cross-linked hyaluronic acid 24 mg/ml (non-animal origin).
- Lidocaine hydrochloride 0.3% as a local anaesthetic for patient comfort.
- Physiological buffered solution and excipients (proprietary) to maintain pH and osmolarity.
- Highly purified HA with low endotoxin and residual cross-linker (BDDE) levels in line with international standards for HA fillers.
Formulation
- Monophasic, fully cross-linked high-density hyaluronic acid gel with lidocaine.
- High viscoelasticity and cohesive, elastic gel structure (500 conditional viscosity index, HIVE structure) supporting lift and contour.
- Designed for deep dermal, subcutaneous or supraperiosteal injection depending on area and technique.
- Non-animal, biotechnologically produced hyaluronic acid, purified and stabilised for aesthetic use.
Packaging
- Box containing 1 x 1.1 ml pre-filled sterile syringe of EQ Eloquence Deep with Lidocaine.
- Supplied with a sterile 27G needle (and, in some packs, a second 27G needle) for injection as specified by the distributor.
- Single-use syringe and needles packaged in a sterile blister within an outer carton showing batch number and expiry date.
- Package includes instructions for use and product labelling in accordance with medical device regulations.
Usage
- For professional use only; injection must be performed by appropriately trained and qualified healthcare practitioners in accordance with local regulations.
- Before treatment, take a complete medical history including allergies, previous filler treatments, medication use (especially anticoagulants/antiplatelets), autoimmune disease and history of hypertrophic scarring or keloids.
- Cleanse and disinfect the treatment area thoroughly and use strict aseptic technique throughout the procedure.
- EQ Eloquence Deep is generally injected into the deep dermis, subcutaneous tissue or supraperiosteal plane, depending on the area (e.g. cheeks, jawline, chin) and clinical objective.
- Use the supplied 27G needle or an appropriate alternative needle/cannula size according to the chosen technique and area.
- Inject slowly with minimal pressure using small aliquots, aspirating where appropriate to reduce the risk of intravascular injection and continually monitoring tissue response.
- Apply gentle massage after injection if necessary to shape the filler and achieve the desired contour, while avoiding excessive pressure.
- Advise patients to avoid strenuous exercise, alcohol, saunas/steam rooms, and intense heat or cold for at least 24–48 hours after treatment, or as per clinic protocol.
- Instruct patients not to touch or apply make-up to treated areas for several hours after the procedure and to follow any additional clinic-specific aftercare instructions.
- Ensure the clinic is equipped and staff are trained to recognise and manage complications, including vascular compromise, hypersensitivity reactions and infection; have emergency protocols and medications (including hyaluronidase) readily available.
- Do not reuse any part of the product; discard the syringe and needles as clinical sharps waste immediately after use.
Contraindications
- Hypersensitivity or known allergy to hyaluronic acid, lidocaine, amide-type local anaesthetics, or any other component of the product.
- Presence of active skin infection, inflammatory skin disease, or herpes simplex at or near the intended injection site.
- History of severe allergic reactions or anaphylaxis without thorough risk assessment and emergency preparedness.
- Autoimmune or connective tissue disorders and immunocompromised states should be evaluated carefully; use only if potential benefits clearly outweigh risks.
- Bleeding disorders or ongoing anticoagulant/antiplatelet therapy that significantly increases bleeding or bruising risk (relative contraindication requiring individual assessment).
- Pregnancy and breastfeeding, due to lack of adequate safety data.
- History of hypertrophic scarring or keloid formation in the area to be treated.
- Previous permanent or semi-permanent fillers in the same area without careful assessment of interactions and risk of granuloma, migration or inflammatory reactions.
Adverse Effects
- Common and usually transient injection site reactions, including redness (erythema), swelling, tenderness, pain, itching, bruising and mild induration or firmness.
- Local haematoma or ecchymosis related to needle or cannula trauma.
- Temporary asymmetry, overcorrection or palpable lumps/nodules, which may resolve spontaneously or require massage or further clinical management.
- Delayed inflammatory reactions or hypersensitivity, presenting as prolonged redness, swelling or induration; may require medical treatment.
- Infection or abscess formation if aseptic technique is not strictly followed or if the area is contaminated after injection.
- Biofilm formation and granuloma development, which may present as persistent nodules and require specialist management.
- Rare but serious adverse events such as vascular occlusion leading to skin blanching, pain, livedo reticularis, tissue ischaemia or necrosis, and, in very rare cases, visual disturbance or blindness if product enters the periocular arterial system.
- Systemic reactions to lidocaine (e.g. dizziness, paraesthesia, palpitations) in cases of significant systemic absorption or inadvertent intravascular injection.
Storage Conditions
- Store in a clean, dry place at a temperature between 2°C and 25°C.
- Do not freeze; avoid exposure to extreme heat or cold.
- Keep the syringe in its original blister and outer carton until immediately before use to maintain sterility and protect from light.
- Do not use the product after the expiry date printed on the packaging.
- Do not use if the packaging is damaged, the sterile blister is compromised, or the syringe/needle appears defective.
- Keep out of the sight and reach of children.
Duration
Clinical effects typically last for approximately 6\u201312 months depending on treatment area, injection technique, volume used, patient metabolism and lifestyle factors such as smoking, sun exposure and physical activity.
Onset
Volume enhancement and contouring are visible immediately after injection, with the final aesthetic result becoming apparent once initial swelling and redness have subsided, usually within several days to around 1\u20132 weeks.
